RCM
EDIT icon

Riverhead Capital Management’s Editas Medicine EDIT Stock Holding History

Riverhead Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,156
Closed -$41K – 1562
2018
Q2 		$41K Sell
1,156
-544
-32% -$19.3K ﹤0.01% 1482
2018
Q1 		$56K Buy
+1,700
New +$60.6K ﹤0.01% 1457

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Riverhead Capital Management's EDIT Position: Q3 2018 in Review

Riverhead Capital Management sold out of Editas Medicine (EDIT) in Q3 2018, closing a stake of 1,156 shares — an estimated $41K sold.

Riverhead Capital Management first reported a position in EDIT in Q1 2018 and held it in 2 quarters. The position peaked at $56K in Q1 2018. 199 funds tracked by Wall St. Rank hold EDIT as of Q3 2018.

  • Riverhead Capital Management reported no remaining Editas Medicine position as of Q3 2018 after selling out during the quarter.
  • Riverhead Capital Management sold 1,156 Editas Medicine shares in Q3 2018, an estimated $41K.
  • Riverhead Capital Management first reported a position in Editas Medicine in Q1 2018 and held it in 2 quarters.
  • Riverhead Capital Management's Editas Medicine position peaked at $56K in Q1 2018.
  • 199 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2018.

Based on Riverhead Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.